 |
|
|---|---|
 |
|
| VISMODEGIB |
Oncology-focused drug development company Curis has obtained the conditional approval for Erivedge (vismodegib) to treat adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy in the European Union (EU)
Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma(BCC). The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval. The drug is also undergoing clinical trials for metastatic colorectal cancer,small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastomaand chondrosarcoma as of June 2011. The drug was developed by the biotechnology /pharmaceutical company Genentech, which is headquartered at South San Francisco, California, USA.
